D'Amico Ferdinando, Parigi Tommaso Lorenzo, Fiorino Gionata, Peyrin-Biroulet Laurent, Danese Silvio
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019.
Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.
托法替布是一种针对JAK/STAT通路的口服小分子药物，可阻断炎症级联反应。托法替布的口服制剂最近已被批准用于治疗中重度溃疡性结肠炎患者。其疗效和安全性已在三项III期临床试验中得到证实，并得到了有前景的真实世界数据的佐证。本综述的目的是总结关于托法替布疗效和安全性的现有证据，并明确其在溃疡性结肠炎患者治疗方案中的作用和地位。
